Tandem Diabetes Care, Inc. filed a Form 8-K on November 13, 2026, disclosing that it received 510(k) clearance from the U.S. Food and Drug Administration on November 12, 2026, for a tubeless configuration of its Tandem Mobi automated insulin delivery system.

Key Highlights

  • FDA clearance received: Tandem Diabetes Care received 510(k) clearance on November 12, 2026, for Tandem Mobi as a tubeless automated insulin delivery system.
  • Wear duration: According to the filing, the tubeless infusion set is cleared for up to 7 days of wear, while the cartridge is cleared for 3 days of use.
  • New components: A new Tandem Mobi tubeless cartridge and infusion set converts the existing Tandem Mobi pump into a tubeless device.
  • Dual-option pump: The filing states the Tandem Mobi pump is now cleared for both tubeless and tubed insulin infusion options.
  • Commercial launch timing: Full commercial launch of the new tubeless cartridge and infusion set is planned for the first half of 2027 in the United States, according to the filing.
  • Technology included: The company disclosed the device offers Control-IQ+ advanced hybrid closed-loop technology.

FDA Clears Tandem Mobi for Tubeless Wear Up to 7 Days

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported in its November 13, 2026 Form 8-K that it received 510(k) clearance from the U.S. Food and Drug Administration on November 12, 2026, for the Tandem Mobi as a tubeless automated insulin delivery system. The company described it as "the world's first and only tubeless automated insulin delivery system with up to 7 days of wear," with the footnoted clarification that the tubeless infusion set is cleared for up to 7 days of wear and the cartridge is cleared for 3 days of use.

According to the filing, a new Tandem Mobi tubeless cartridge and infusion set is designed to convert the current Tandem Mobi pump into a tubeless device, with the stated aim of allowing less frequent site changes. The filing notes that the device incorporates Control-IQ+ advanced hybrid closed-loop technology. With this clearance, the company disclosed that the Tandem Mobi pump is now cleared for both tubeless and tubed insulin infusion options, which the company characterized as giving users "the flexibility to choose the wear option that best meets their needs."

The filing states that full commercial launch of the tubeless cartridge and infusion set is planned for the first half of 2027 in the United States. The company noted that statements about planned launch timing are forward-looking statements subject to numerous risks and uncertainties, including risks related to safety, regulatory clearance, supply and manufacturing, and other factors identified in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

What Was Disclosed

Tandem Diabetes Care disclosed receipt of FDA 510(k) clearance on November 12, 2026, for a tubeless configuration of the Tandem Mobi pump, with the new tubeless cartridge and infusion set targeting a commercial launch in the first half of 2027 in the United States.